Lack of Adequate Study Plan Prompts EMA Review Of Cardiovascular Risk With Mysimba

 
• By Neena Brizmohun
  
obese heart
The EMA is reviewing the cardiovascular risk with obesity drug Mysimba • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Europe

More from Geography